A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of MGA012 in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of MGA012 in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs MGA 012 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors MacroGenics
  • Most Recent Events

    • 25 Oct 2017 According to an Incyte Corporation media release, data from dose escalation portion have been accepted for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting 2017.
    • 25 Oct 2017 According to an Incyte Corporation media release, enrollment in the dose escalation portion of the trial has been completed.
    • 02 Aug 2017 According to a MacroGenics media release, patients are being enrolled in the dose escalation segment of the study and expects to define a target dose and schedule soon.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top